Advisory Committee to the Director, Centers for Disease Control and Prevention, (ACD, CDC), 10050 [E9-4940]
Download as PDF
<![CDATA[
10050
Federal Register / Vol. 74, No. 44 / Monday, March 9, 2009 / Notices
PACHA Committee Manager is listed
above.
CONTACT PERSON FOR MORE INFORMATION:
Dated: March 3, 2009.
Christopher H. Bates,
Interim Executive Director, Presidential
Advisory Council on HIV/AIDS.
[FR Doc. E9–4854 Filed 3–6–09; 8:45 am]
BILLING CODE 4150–43–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
dwashington3 on PROD1PC60 with NOTICES
Advisory Committee to the Director,
Centers for Disease Control and
Prevention, (ACD, CDC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the CDC announces
the following meeting of the
aforementioned committee:
TIME AND DATE: 6 p.m.–7 p.m., March 4,
2009.
PLACE: The teleconference call will
originate at the CDC. Details on
accessing the teleconference are located
in the supplementary information.
STATUS: Open to the public,
teleconference access limited only by
availability of telephone ports.
PURPOSE: The committee will provide
advice to the Director, CDC on strategic
and other broad issues facing CDC.
MATTERS TO BE DISCUSSED: During this
conference call, the National
Biosurveillance Advisory Subcommittee
(NBAS) will provide recommendations
to the ACD, CDC for transmittal to the
administration. Since the NBAS was
created in May, 2008, the subcommittee
has been on a very aggressive timeline
in order to provide the administration
with key recommendations for
improving the nation’s biosurveillance
capability. In order for these
recommendations to go through the
proper clearance steps and still be
timely and relevant for the
administration, the ACD, CDC must
review and approve these
recommendations as soon as possible.
The NBAS was originally scheduled to
present these recommendations to the
ACD, CDC at the meeting scheduled for
February 24, 2009.
Agenda items are subject to change as
priorities dictate.
SUPPLEMENTARY INFORMATION: This
conference call is scheduled to begin at
6 p.m. Eastern Standard Time. To
participate in the teleconference, please
dial 1–888–323–9787 and enter
conference code 4735949.
VerDate Nov<24>2008
15:28 Mar 06, 2009
Jkt 217001
Brad Perkins, M.D., M.B.A., Designated
Federal Officer, ACD, CDC, 1600 Clifton
Road, NE., M/S D–14, Atlanta, Georgia
30333. Telephone: 404–639–7000.
The ACD, CDC was scheduled to meet
by conference call on February 24, 2009.
The meeting was postponed on short
notice because of quorum guidelines.
The meeting is re-scheduled for March
4, 2009, at 6 p.m., as this is the only
available time to gather a quorum of the
ACD members.
This notice is being published less
than 15 days prior to the meeting due
to the scheduling difficulties
encountered when planning the
meeting, and due to the urgent nature of
transmitting the recommendations to
the administration.
The Director, Management Analysis
and Services office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the CDC
and the Agency for Toxic Substances
and Disease Registry.
Andre Tyler,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention (CDC).
[FR Doc. E9–4940 Filed 3–4–09; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–R–245]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
AGENCY: Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the Agency’s function;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Medicare and
Medicaid Programs OASIS Collection
Requirements as Part of the CoPs for
HHAs and Supporting Regulations in 42
CFR, Sections 484.55, 484.205, 484.245,
484.250; Use: The Centers for Medicare
& Medicaid Services is requesting OMB
approval to modify the Outcome and
Assessment Information Set (OASIS)
data set that home health agencies
(HHAs) are required to collect in order
to participate in the Medicare program.
Proposed revisions to the OASIS data
set include: (1) Issues raised by
stakeholders, including removing items
that are not currently used by CMS for
payment or quality, adding items to
address clinical domains not currently
covered, and modifying item wording or
response categories for selected items;
and (2) the addition of process items
that support measurement of evidencebased practices. Proposed revisions to
OASIS items address issues raised by
stakeholders, including removing items
that are not currently used by CMS for
payment or quality, adding items to
address clinical domains not currently
covered, and modifying item wording or
response categories for selected items.
These changes and item deletions are
considered to be high priority by CMS
and have implications for outcome
measurement, risk adjustment of
outcome reports, case mix adjustment
for prospective payment, data
submission procedures and
specifications, reporting systems, and
provider paperwork burden.
In addition, adopting measures of
efficient and high-quality care is central
to the direction that CMS would like to
take in its Quality Initiative. In
accordance with long-standing Federal
objectives, CMS ultimately plans to
create a standard patient assessment
instrument that can be used across all
post-acute care settings. The revision of
the OASIS instrument is an opportunity
to consider various components of
quality care and how patients might be
better served as they (and information
about them and their care) move among
health care settings. For this reason, the
OASIS C includes process items that
support measurement of evidence-based
practices across the post-acute care
spectrum that have been shown to
prevent exacerbation of serious
conditions, can improve care received
by individual patients, and can provide
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 74, Number 44 (Monday, March 9, 2009)]
[Notices]
[Page 10050]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-4940]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee to the Director, Centers for Disease Control
and Prevention, (ACD, CDC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the CDC announces the following meeting
of the aforementioned committee:
Time and Date: 6 p.m.-7 p.m., March 4, 2009.
Place: The teleconference call will originate at the CDC. Details on
accessing the teleconference are located in the supplementary
information.
Status: Open to the public, teleconference access limited only by
availability of telephone ports.
Purpose: The committee will provide advice to the Director, CDC on
strategic and other broad issues facing CDC.
Matters To Be Discussed: During this conference call, the National
Biosurveillance Advisory Subcommittee (NBAS) will provide
recommendations to the ACD, CDC for transmittal to the administration.
Since the NBAS was created in May, 2008, the subcommittee has been on a
very aggressive timeline in order to provide the administration with
key recommendations for improving the nation's biosurveillance
capability. In order for these recommendations to go through the proper
clearance steps and still be timely and relevant for the
administration, the ACD, CDC must review and approve these
recommendations as soon as possible. The NBAS was originally scheduled
to present these recommendations to the ACD, CDC at the meeting
scheduled for February 24, 2009.
Agenda items are subject to change as priorities dictate.
SUPPLEMENTARY INFORMATION: This conference call is scheduled to begin
at 6 p.m. Eastern Standard Time. To participate in the teleconference,
please dial 1-888-323-9787 and enter conference code 4735949.
Contact Person for More Information: Brad Perkins, M.D., M.B.A.,
Designated Federal Officer, ACD, CDC, 1600 Clifton Road, NE., M/S D-14,
Atlanta, Georgia 30333. Telephone: 404-639-7000.
The ACD, CDC was scheduled to meet by conference call on February
24, 2009. The meeting was postponed on short notice because of quorum
guidelines. The meeting is re-scheduled for March 4, 2009, at 6 p.m.,
as this is the only available time to gather a quorum of the ACD
members.
This notice is being published less than 15 days prior to the
meeting due to the scheduling difficulties encountered when planning
the meeting, and due to the urgent nature of transmitting the
recommendations to the administration.
The Director, Management Analysis and Services office has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the CDC and the Agency for Toxic Substances and Disease Registry.
Andre Tyler,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention (CDC).
[FR Doc. E9-4940 Filed 3-4-09; 4:15 pm]
BILLING CODE 4163-18-P
